Literature DB >> 11153777

No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium.

H M Siebelink1, P K Blanksma, H J Crijns, J J Bax, A J van Boven, T Kingma, D A Piers, J Pruim, P L Jager, W Vaalburg, E E van der Wall.   

Abstract

OBJECTIVES: We sought to prospectively compare nitrogen-13 (13N)-ammonia/18fluorodeoxyglucose (18FDG) positron emission tomography (PET)-guided management with stress/rest technetium-99m (99mTc)-sestamibi single-photon emission computed tomography (SPECT)-guided management.
BACKGROUND: Patients with evidence of jeopardized (i.e., ischemic or viable) myocardium may benefit from revascularization, whereas patients without it should be treated with drugs. Both PET and SPECT imaging have been proven to delineate jeopardized myocardium. When patient management is based on identification of jeopardized myocardium, it is unknown which technique is most accurate for long-term prognosis.
METHODS: In a clinical setting, 103 patients considered for revascularization with left ventricular wall motion abnormalities and suspicion of jeopardized myocardium underwent both PET and SPECT imaging. The imaging results were used in a randomized fashion to determine management (percutaneous transluminal coronary angioplasty [PTCA], coronary artery bypass graft surgery [CABG] or drug treatment). Follow-up for cardiac events (cardiac death, myocardial infarction and revascularization) was recorded for 28 +/- 1 months. The study was designed to have a power of 80% to detect a 20% difference in the event rate between PET- and SPECT-based management.
RESULTS: Management decisions in 49 patients randomized to PET (12 who had PTCA, 14 CABG and 23 drug therapy) were comparable with 54 patients randomized to SPECT (15 who had PTCA, 13 CABG and 26 drug therapy). In terms of cardiac event-free survival, no differences between PET and SPECT were observed (11 vs. 13 cardiac events for PET and SPECT, respectively; p = NS by the Kaplan-Meier statistic).
CONCLUSIONS: No difference in patient management or cardiac event-free survival was demonstrated between management based on 13N-ammonia/18FDG PET and that based on stress/rest 99mTc-sestamibi SPECT imaging. Both techniques may be used for management of patients considered for revascularization with suspicion of jeopardized myocardium.

Entities:  

Mesh:

Year:  2001        PMID: 11153777     DOI: 10.1016/s0735-1097(00)01087-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  31 in total

Review 1.  The historical and conceptual evolution of radionuclide assessment of myocardial viability.

Authors:  James E Udelson; Robert O Bonow; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2004 May-Jun       Impact factor: 5.952

Review 2.  Multimodality imaging for assessment of myocardial viability: nuclear, echocardiography, MR, and CT.

Authors:  James A Arrighi; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

3.  Facts and principles learned at the 31st Annual Williamsburg Conference on Heart Disease.

Authors:  Mark A Peterman; Hassan Farooq; William C Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-04

4.  FDG imaging should be considered the preferred technique for accurate assessment of myocardial viability: against.

Authors:  Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

5.  The price for probability: Comparing the costs of diagnostic testing strategies.

Authors:  Prem Soman; James E Udelson
Journal:  J Nucl Cardiol       Date:  2007-04       Impact factor: 5.952

6.  Rabbit models: ideal for imaging purposes?

Authors:  A van der Laarse; E E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2008-12-16       Impact factor: 2.357

Review 7.  Present and future of clinical cardiovascular PET imaging in Europe--a position statement by the European Council of Nuclear Cardiology (ECNC).

Authors:  D Le Guludec; R Lautamäki; J Knuuti; J J Bax; F M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-26       Impact factor: 9.236

Review 8.  Role of myocardial perfusion imaging for risk stratification in suspected or known coronary artery disease.

Authors:  N K Sabharwal; A Lahiri
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

9.  Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute.

Authors:  Pamela S Douglas; Allen Taylor; Diane Bild; Robert Bonow; Philip Greenland; Michael Lauer; Frank Peacock; James Udelson
Journal:  JACC Cardiovasc Imaging       Date:  2009-07

Review 10.  Prognostic and therapeutic implications of myocardial viability in patients with heart failure.

Authors:  Prem Soman; James E Udelson
Journal:  Curr Cardiol Rep       Date:  2004-05       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.